Agilent Technologies
A
$130.59
+0.58%
Agilent Technologies Inc. is a leading global provider of life sciences, diagnostics, and applied chemical markets solutions, operating primarily in the Medical - Diagnostics & Research industry. The company is a market leader in measurement technologies, serving a broad customer base through its three core segments: Life Sciences and Applied Markets, Agilent CrossLab, and Applied Markets, with a significant and stable revenue stream from the biopharmaceutical and chemical sectors. The current investor narrative is focused on the company's strategic expansion into high-growth areas like pathology through acquisitions, such as the recent purchase of Biocare Medical, and its ability to deliver strong quarterly results that exceed expectations and lead to raised full-year profit forecasts, signaling robust operational momentum in a challenging macroeconomic environment.…
A
Agilent Technologies
$130.59
Related headlines
A 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Agilent Technologies's 12-month outlook, with a consensus price target around $169.77 and implied upside of +30.0% versus the current price.
Average Target
$169.77
7 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
7
covering this stock
Price Range
$104 - $170
Analyst target range
Analyst coverage for Agilent is substantial, with 9 analysts providing estimates for the upcoming period, indicating strong institutional interest. The consensus sentiment leans bullish, as evidenced by recent institutional ratings from major firms like Morgan Stanley, Barclays, UBS, and Wells Fargo maintaining 'Overweight' or 'Buy' equivalents, and an upgrade from Evercore ISI Group to 'Outperform' in January 2026. The average revenue estimate for the next period is $9.37 billion, with a tight range between $9.29 billion and $9.45 billion, and the average EPS estimate is $8.82, ranging from $8.72 to $8.92, signaling high conviction in near-term financial performance. The target price range is not explicitly provided in the data, but the presence of multiple 'Buy' or 'Overweight' ratings from reputable firms suggests the consensus view is positive, with the implied upside or downside dependent on the specific average target price, which is not available in the provided dataset; however, the recent news of a strong quarterly beat and raised guidance likely supports upward target revisions. The relatively narrow range between the low and high EPS estimates (a spread of only $0.20) indicates strong analyst agreement on the company's near-term earnings power, reducing uncertainty, while the recent upgrade activity points to improving sentiment following the Q1 2026 results.
Bulls vs Bears: A Investment Factors
The evidence presents a classic battle between strong company-specific fundamentals and weak technical/momentum indicators. The bull case is anchored in Agilent's high-quality business model, recent earnings strength, raised guidance, and solid financials. The bear case highlights the stock's severe technical underperformance, margin compression, and premium valuation. Currently, the bearish technical picture and valuation concerns hold stronger near-term evidence, as the stock's 1-year underperformance of -13.7% relative to the S&P 500 is stark. The single most important tension in the investment debate is whether the company's robust operational momentum (Q1 beat, raised guidance) can overcome the significant valuation compression and negative market sentiment that has driven the stock to the lower end of its 52-week range. The resolution of this tension hinges on the sustainability of margin recovery and sequential revenue growth in upcoming quarters.
Bullish
- Strong Q1 Beat & Raised Guidance: The company's recent Q1 FY2026 earnings significantly exceeded expectations, leading to a raised full-year profit forecast. This signals robust operational momentum and strong execution, which was the catalyst for the recent 15%+ one-month rally in the stock price.
- High-Quality, Stable Business Model: Agilent's largest segment, Agilent CrossLab ($758M in Q1), provides stable, recurring revenue from consumables and services. Over half of sales come from sticky biopharmaceutical and chemical end markets, supporting a strong gross margin of 52.61% and consistent free cash flow generation of $993M TTM.
- Solid Financial Health & Capital Return: The company boasts a robust balance sheet with a current ratio of 1.96 and a conservative debt-to-equity ratio of 0.50. This financial strength supports a 0.68% dividend yield, share repurchases, and strategic acquisitions like Biocare Medical to fuel growth.
- Analyst Consensus Bullish with High Conviction: Analyst sentiment is positive, with major firms maintaining 'Overweight' or 'Buy' ratings and a recent upgrade to 'Outperform'. The narrow range between high and low EPS estimates ($8.72 to $8.92) indicates strong agreement on near-term earnings power, reducing uncertainty.
Bearish
- Significant Technical Downtrend & Underperformance: The stock is down 5.9% YTD and has underperformed the S&P 500 by nearly 14% over the past year. Trading near the lower 25% of its 52-week range ($108.35-$160.27) indicates deep technical damage and negative momentum that may persist.
- Earnings & Margin Compression: While Q1 revenue grew 6.96% YoY, it declined sequentially from Q4. More concerning, net margin compressed sharply to 16.96% from 23.32% in the prior quarter, indicating significant cyclical or operational pressure on profitability.
- Elevated Trailing Valuation Metrics: Despite the price decline, the trailing P/E of 31.79x and P/S of 5.96x remain at a premium to likely sector averages. The high PEG ratio of 9.41 suggests growth expectations are already fully priced in, leaving little room for error.
- High Beta & Market Sensitivity: With a beta of 1.256, Agilent is approximately 26% more volatile than the broader market. This amplifies downside risk during market corrections, as evidenced by its -29.87% max drawdown, and makes the stock susceptible to macro-driven sell-offs.
A Technical Analysis
The stock is in a sustained downtrend over the past year, with a 1-year price change of +9.19% significantly underperforming the S&P 500's +22.86% gain, as indicated by a -13.67 relative strength. The current price of $129.84 is trading near the lower end of its 52-week range of $108.35 to $160.27, positioning it at approximately 25% of that range, which suggests the stock is in a deep correction and may present a value opportunity if fundamentals hold, but also indicates significant technical damage and negative momentum. Recent short-term momentum shows a sharp but volatile recovery, with a 1-month price change of +15.17% and a 3-month change of +16.44%, which strongly diverges from the weaker 6-month and YTD performance of -7.04% and -5.88%, respectively; this suggests a potential trend reversal or a significant relief rally from oversold conditions, though it remains below the highs seen earlier in the period. Key technical levels are clear, with immediate resistance at the 52-week high of $160.27 and strong support at the 52-week low of $108.35; a sustained breakout above the recent recovery high near $148 would be needed to signal a more durable uptrend, while a break below the $108 support could trigger further declines. The stock's beta of 1.256 indicates it is approximately 26% more volatile than the broader market, which is important for risk management as it suggests amplified moves in both directions.
Beta
1.26
1.26x market volatility
Max Drawdown
-29.9%
Largest decline past year
52-Week Range
$108-$160
Price range past year
Annual Return
+11.5%
Cumulative gain past year
| Period | A Return | S&P 500 |
|---|---|---|
| 1m | +16.9% | +2.1% |
| 3m | +15.8% | +12.5% |
| 6m | -4.4% | +12.4% |
| 1y | +11.5% | +26.4% |
| ytd | -5.3% | +10.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
A Fundamental Analysis
Agilent's revenue trajectory shows modest growth but recent quarterly deceleration; Q1 FY2026 revenue was $1.798 billion, representing a year-over-year growth of 6.96% from the prior-year quarter's $1.681 billion, but this marks a sequential decline from Q4 FY2025 revenue of $1.861 billion. The revenue segment data for the latest quarter shows Agilent CrossLab contributing $758 million, Life Sciences and Applied Markets at $679 million, and Applied Markets at $361 million, indicating the services and consumables-focused CrossLab segment is the largest contributor, providing stability. The company remains solidly profitable with a Q1 net income of $305 million, translating to a net margin of 16.96%, and maintains a strong gross margin of 52.61%, which is consistent with its historical profile and the high-margin nature of its consumables and services business. However, profitability has compressed from the prior quarter's net margin of 23.32%, indicating some cyclical or operational pressure on earnings. The balance sheet and cash flow position are robust, with a healthy current ratio of 1.96 and a manageable debt-to-equity ratio of 0.50, reflecting a conservative capital structure. The company generated substantial free cash flow of $993 million over the trailing twelve months and $175 million in the latest quarter, providing ample liquidity for dividends, share repurchases, and strategic acquisitions like Biocare Medical, while its return on equity of 19.33% demonstrates efficient use of shareholder capital.
Quarterly Revenue
$1.8B
2026-01
Revenue YoY Growth
+0.06%
YoY Comparison
Gross Margin
+0.52%
Latest Quarter
Free Cash Flow
$993000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is A Overvalued?
Given the company's consistent profitability with a positive net income, the primary valuation metric selected is the Price-to-Earnings (P/E) ratio. The trailing P/E ratio is elevated at 31.79x, while the forward P/E is significantly lower at 19.65x, indicating the market is pricing in a substantial recovery in earnings growth over the next twelve months. Compared to sector averages (data not explicitly provided in the input, but typical for the industry), a trailing P/E of 31.79x is likely at a premium, reflecting Agilent's market leadership, high margins, and stable business model; the forward P/E of 19.65x would narrow this premium considerably if earnings estimates are met. Historically, the stock's own P/E ratio has fluctuated, with recent quarterly data showing a range from approximately 24x to over 36x over the past two years; the current trailing multiple of 31.79x sits above the midpoint of this recent historical range, suggesting the market is not pricing the stock at a deep discount despite its significant price decline from highs, implying expectations for a earnings rebound are already embedded. The Price-to-Sales ratio of 5.96x and EV/Sales of 5.30x provide additional context, confirming the stock trades at a premium sales multiple consistent with its quality profile.
PE
31.8x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 16x~81x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
23.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Agilent faces near-term profitability pressure, with Q1 net margin compressing to 16.96% from 23.32% the prior quarter. While revenue grew 6.96% YoY, the sequential decline from Q4 to Q1 raises concerns about growth sustainability. The company's valuation remains elevated with a trailing P/E of 31.79x and a P/S of 5.96x, creating dependency on continued high earnings growth to justify its price. However, these risks are mitigated by a strong balance sheet (D/E of 0.50) and robust free cash flow generation ($993M TTM), providing a cushion for strategic moves and shareholder returns.
Market & Competitive Risks: The primary market risk is valuation compression. The stock's high trailing multiples trade at a significant premium, making it vulnerable to sector rotation out of growth/quality names, especially if interest rates remain elevated. Its beta of 1.256 indicates it will experience amplified moves during market downturns. Competitive risks include disruption in its core life sciences and diagnostics markets, though its leadership position and recent acquisition (Biocare Medical) aim to bolster its moat. Recent news highlights a bifurcated market favoring pure AI plays, potentially diverting investor attention and capital away from steadier compounders like Agilent.
Worst-Case Scenario: The worst-case scenario involves a failure to arrest margin compression combined with a broader market sell-off that triggers multiple compression for premium-valued stocks. In this scenario, deteriorating earnings (Q1 net income of $305M vs. Q4's $434M) could lead to missed forward estimates, analyst downgrades, and a re-rating towards its historical valuation lows. A realistic downside could see the stock retesting its 52-week low of $108.35, representing a potential loss of approximately -17% from the current price of $129.84. The stock's -29.87% max drawdown demonstrates this magnitude of decline is within recent historical precedent.